Great article at the wall street journal :Curing Hepatitis C Will Take More Than New Treatments
"Pivotal trials have shown that the two therapies farthest along in development — telaprevir from Johnson & Johnson and Vertex Pharmaceuticals, and boceprevir from Merck — are more likely to cure hepatitis C than currently available treatment. There’s widespread anticipation the pills will win FDA approval next year. And they could be followed by the introduction of even more new therapies, the WSJ reports".
No comments:
Post a Comment